Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 445-455

  Reaman, Gregory H ^a   Sposto, Richard ^a   Sensel, Martha G ^a   Lange, Beverly J ^a   Feusner, James H ^a   Heerema, Nyla A ^a   Leonard, Marcia ^a   Holmes, Emiko J ^a   Sather, Harland N ^a   Pendergrass, Thomas W ^a   Johnstone, Helen S ^a   O'Brien, Richard T ^a   Steinherz, Peter G ^a   Zeltzer, Paul M ^a   Gaynon, Paul S ^a   Trigg, Michael E ^a   Uckun, Fatih M ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; FOLINATE CALCIUM; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ARTICLE; BLOOD TOXICITY; BONE MARROW DISEASE; BRAIN LEUKEMIA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILDHOOD CANCER; CHROMOSOME TRANSLOCATION 4; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; INFANT; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEPSIS;

EID: 0033015207     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.445     Document Type: Article

References (33)

1. Frankel LS, Ochs J, Shuster JJ, et al: Therapeutic trial for infant acute lymphoblastic leukemia: The Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol 19:35-42, 1997
2. Reaman G, Zeltzer P, Bleyer WA, et al: Acute lymphoblastic leukemia in infants less than one year of age: A cumulative experience of the Children's Cancer Study Group. J Clin Oncol 3:1513-1521, 1985
3. Reaman GH, Steinherz PG, Gaynon PS, et al: Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Cancer Treat Rep 71:1033-1038, 1987
4. Ferster A, Bertrand Y, Benoit Y, et al: Improved survival for acute lymphoblastic leukaemia in infancy: The experience of EORTC-Childhood Leukaemia Cooperative Group. Br J Haematol 86:284-290, 1994
5. Ishii E, Okamura J, Tsuchida M, et al: Infant leukemia in Japan: Clinical and biological analysis of 48 cases. Med Pediatr Oncol 19:28-32, 1991
6. Bucsky P, Reiter A, Ritter J, et al: [Acute lymphoblastic leukemia in infancy: Results of 5 multicenter ALL-BFM therapy studies 1970-1986]. Klin Padiatr 200:177-183, 1988
7. Chessells JM, Eden OB, Bailey CC, et al: Acute lymphoblastic leukaemia in infancy: Experience in MRC UKALL trials - Report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia 8:1275-1279, 1994
8. Basso G, Putti MC, Cantu Rajnoldi A, et al: The immunophenotype in infant acute lymphoblastic leukaemia: Correlation with clinical outcome - An Italian multicentre study (AIEOP). Br J Haematol 81:184-191, 1992
9. Ludwig WD, Bartram CR, Harbott J, et al: Phenotypic and genotypic heterogeneity in infant acute leukemia: I. Acute lymphoblastic leukemia. Leukemia 3:431-439, 1989
10. Pui CH, Ribeiro RC, Campana D, et al: Prognostic factors in the acute lymphoid and myeloid leukemias of infants. Leukemia 10:952-956, 1996
11. Cimino G, Rapanotti MC, Rivolta A, et al: Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias. Leukemia 9:391-395, 1995
12. Pui CH, Behm FG, Downing JR, et al: 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 12:909-915, 1994
13. Taki T, Ida K, Bessho F, et al: Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia. Leukemia 10:1303-1307, 1996
14. Behm FG, Raimondi SC, Frestedt JL, et al: Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 87:2870-2877, 1996
15. Heerema NA, Arthur DC, Sather H, et al: Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: Impact of the 11q23 breakpoint on outcome - A report of the Children's Cancer Group. Blood 83:2274-2284, 1994
16. Hilden JM, Frestedt JL, Moore RO, et al: Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4;11)(q21;q23). Blood 86:3876-3882, 1995
17. Uckun FM, Ledbetter JA: Immunobiologic differences between normal and leukemic human B-cell precursors. Proc Natl Acad Sci USA 85:8603-8607, 1988
18. + acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. Blood 73:1000-1015, 1989
19. Heerema NA, Palmer CG, Baehner RL: Karyotypic and clinical findings in a consecutive series of children with acute lymphocytic leukemia. Cancer Genet Cytogenet 17:165-179, 1985
20. Mitelman F: ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1995
21. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley and Sons, 1980
22. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
23. Gaynor J, Feuer E, Tan C, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
24. Coccia PF, Bleyer WA, Siegel SE, et al: Development and Preliminary Findings of Children's Cancer Study Group Protocols (161, 162 and 163) for Low-, Average-and High-Risk Acute Lymphoblastic Leukemia in Children, in Murphy S, Gilbert J (eds): Leukemia Research: Advances in Cell Biology and Treatment. Amsterdam, the Netherlands, Elsevier Science Publishing Co, 1983
25. Kaleita TA, MacLean WE, Reaman GH, et al: Neurodevelopmental outcome of children diagnosed with all during infancy: A preliminary report from the Children's Cancer Study Group. Med Pediatr Oncol 20:385, 1992
26. Steinherz PG, Gaynon PS, Breneman JC, et al: Cytoreduction and prognosis in acute lymphoblastic leukemia-the importance of early marrow response: Report from the Children's Cancer Group. J Clin Oncol 14:389-398, 1996
27. Gaynon PS, Bleyer WA, Steinherz PG, et al: Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 18:273-279, 1990
28. Rubnitz JE, Link MP, Shuster JJ, et al: Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 84:570-573, 1994
29. + B-progenitor immunophenotype in children with acute lymphoblastic leukemia: A report from the Children's Cancer Group. Leuk Lymphoma 27:445-457, 1997
30. Silverman L, McLean T, Gelber R, et al: Intensified therapy for infants with acute lymphoblastic leukemia. Cancer 80:2285-2296, 1997
31. Appelbaum FR: Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin Oncol 24:114-123, 1997
32. Uckun FM, Manivel C, Arthur D, et al: In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 79:2201-2214, 1992
33. Uckun FM, Evans WE, Forsyth CJ, et al: Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 267:886-891, 1995